SAGES Magazine

ferric carboxymaltose Helping your patients with ID/IDA* get back to what matters Clinically meaningful improvements 1,2 Up to 99 % red cell utilisation rates 3,6 A dextran-free i.v. iron product 3-5 Fewer visits and shorter administration time to administer 1 000 mg iron 8 15 min 31 company-sponsored published randomised interventional clinical trials 7 Extensive patient-years experience 9 Choose Ferinject®: 16 million patient-years of experience since launch 9 * ID = iron deficiency; IDA = iron deficiency anaemia Reference: 1. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT) Randomized Controlled Trial. Am J Gastroenterol 2007; 102 :1–11. 2. Van Wyck DB, Mangoine, A, Morrison J, Hadley PE, Jehle JA, Goodnough LT for the Ferric Carboxymaltose Study Group. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49 (12):2719-2728. 3. Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009; 23 (1):11. 4. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung 2010; 60 (6a):362-372. 5. Neiser S, WilhelmM, Schwarz K, Funk F, Geisser P, Burckhardt S. Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay. Port J Nephrol Hypert 2011; 25 (3):219-224. 6. Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, Antoni G, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120 :853-859. 7. Ferinject®: Updated list of Ferinject® exposure based on published RCTS, 10 Nov 2020. 8. Ferinject® Package Insert. Takeda, South Africa. 6 March 2014. 9. Vifor, Data on file, 1 Jan 2021. S3 FERINJECT® Solution for infusion/Injection. Reg. No.: 45/8.3/0948. Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. For full prescribing information refer to the professional information approved by the medicines regulatory authority (07/2021). FERINJECT® is a registered trademark of Vifor Pharma and is used under license. © 2021 Aspen Group of companies or its licensor. All rights reserved. Marketed by Aspen Pharmacare for Pharmacare Limited. Co. Reg. No.: 1898/000252/06. Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-FEC-08-21-00004 08/2021.